Loading clinical trials...
Loading clinical trials...
Browse 3,654 clinical trials for depression. Find studies that match your criteria and connect with research centers.
Find trials near:
Showing 281-300 of 3,654 trials
NCT07395700
This observational study evaluates the psychometric properties of the Behavioral Activation for Depression Scale (BADS) in individuals with substance use disorders. The study examines the scale's internal structure, reliability, and validity using data from 289 participants who completed the BADS. External and incremental validity analyses were conducted in a subsample of 127 participants for whom additional clinical measures were available, including assessments of symptom severity, anxiety, impulsivity, and anger expression. This approach reflects the availability of complete data for each analytic component and allows for a comprehensive evaluation of the BADS in a clinical population.
NCT05877287
This research was planned to examine the effect of mindfulness-based stress reduction program applied to parents with autistic children on the level of depression, anxiety, stress and hopelessness.
NCT07398053
In Belgium, many adults who have suffered from depression keep using antidepressants on a daily basis for years afterwards, sometimes longer than guidelines recommend. Yet for some people who have been feeling well for a long time, this is no longer necessary, while the continued use of antidepressants can lead to side effects and causes additional costs for the healthcare system. However, reducing the doses of antidepressants or stopping altogether is not always easy. Some patients are afraid that their depression will return, and GPs and pharmacists often find the subject difficult to broach. This is why the GPS-AD study is investigating a new approach in which GPs and pharmacists work more closely together to provide better support to patients. First, the GP invites patients who have been taking antidepressants for a long time for a consultation. Together, they discuss whether tapering of the medication is reasonable and feasible. If they agree to stop the treatment, the GP draws up a tapering plan tailored to the patient. The pharmacist helps monitor this process, offering advice and support to the patient while the doses are gradually reduced. The study will extend over a period of two years and will take place in GP practices throughout Belgium. The new approach based on closer collaboration between GPs and pharmacists will be compared to the current standard of care, to determine whether it helps more long-term users to stop taking antidepressants without experiencing a recurrence of depressive symptoms. The name of the study, GPS-AD (General Practitioner and Pharmacist Support for Antidepressant Discontinuation), refers to the collaboration between GPs and pharmacists in tapering of antidepressants, and also symbolises the support and guidance (the 'GPS') provided to patients and healthcare providers in assessing whether long-term use of antidepressants is still necessary.